TrialsgrambetaRCTs are beautiful

DELIVER

2022

Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved-EF Heart Failure

In 6,263 patients with heart failure and an ejection fraction > 40 %, dapagliflozin reduced worsening heart failure or cardiovascular death compared with placebo.

Result

Efficacy: Worsening HF or CV deathHR 0.82

Below 1 favours dapagliflozin, above 1 favours placebo.

Event rates
Absolute difference
3.1 points

The absolute difference is derived from the event rates.

Also reported: Benefit consistent across the EF spectrum.

Original publication
Subtopic
SGLT2 inhibitors
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Solomon SD, et al. N Engl J Med. 2022;387(12):1089-1098.doi 10.1056/NEJMoa2206286

Discussion & critique

With EMPEROR-Preserved, made SGLT2 inhibitors the first broadly effective HFpEF therapy. Driven by HF events; mortality not significantly reduced.

Discussed in podcasts